Robert Kramer - EMERGENT BIOSOLUT President
| ER4 Stock | EUR 9.49 0.01 0.11% |
President
Mr. Robert G. Kramer Sr., is re designated as President, Chief Executive Officer, Director of the Company since April 2019. He served as our president and chief operating officer from March 2018 to March 2019. Previously, he also served as our executive vice president, administration, chief financial officer and treasurer from September 2012 until his promotion to president and chief operating officer in March 2018. Mr. Kramer first joined us in 1999 as our chief financial officer. From 1999 until his prior retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division. Prior to joining us in 1999, Mr. Kramer held various financial management positions at Pharmaci Corporationrationration, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc since 2019.
| Age | 61 |
| Tenure | 5 years |
| Professional Marks | MBA |
Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Ann Tripp | The Hanover Insurance | 60 | |
| Warren Barnes | The Hanover Insurance | 57 | |
| Bryan Salvatore | The Hanover Insurance | 58 | |
| Jeffrey Farber | The Hanover Insurance | 58 | |
| Mark Welzenbach | The Hanover Insurance | 59 | |
| Fernando Mulet | Playa Hotels Resorts | 47 | |
| Mark Berthiaume | The Hanover Insurance | 62 | |
| John Roche | The Hanover Insurance | 59 | |
| Richard Lavey | The Hanover Insurance | 55 | |
| John Mulleady | Dave Busters Entertainment | 62 | |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
| Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Marvin White, Director | ||
| Kathryn Zoon, Independent Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Independent Director | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.